Cellectis (Cellectis) Net Cash per Share

: $-1.19 (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Cellectis's Net Cash per Share for the quarter that ended in Sep. 2023 was $-1.19.

The historical rank and industry rank for Cellectis's Net Cash per Share or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Cash Ratio of Cellectis was 18.66. The lowest was 1.92. And the median was 4.21.

CLLS's Price-to-Net-Cash is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.875
* Ranked among companies with meaningful Price-to-Net-Cash only.

Cellectis Net Cash per Share Historical Data

The historical data trend for Cellectis's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Cash per Share

Get a 7-Day Free Trial

8.49

4.91

1.93

0.56

-1.00

Cellectis Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Net Cash per Share	Get a 7-Day Free Trial															-0.53	-1.00	-0.89	-0.82	-1.19

Competitive Comparison

For the Biotechnology subindustry, Cellectis's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cellectis Price-to-Net-Cash Distribution

For the Biotechnology industry and Healthcare sector, Cellectis's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Cellectis's Price-to-Net-Cash falls into.

Cellectis Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Cellectis's Net Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as

	Net Cash per Share (A: Dec. 2022 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(97.696	-	135.275	-	7.973)	/	45.676
=	-1.00

Cellectis's Net Cash per Share for the quarter that ended in Sep. 2023 is calculated as

	Net Cash per Share (Q: Sep. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(67.358	-	133.577	-	0)	/	55.5838
=	-1.19

Cellectis (NAS:CLLS) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Cellectis Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Cellectis's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectis (Cellectis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

CMVLF:USA 0WA2:UK ALCLS:France ZVAA:Germany

Address

8, rue de la Croix Jarry, Paris, FRA, 75013

Website

https://www.cellectis.com

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.